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1. INTRODUCTION
A profound and accurate knowledge of cancer epidemiology pro-
vides essential information on possible causes and population 
trends of these conditions, thus making it possible to establish 
timely and appropriate health-care interventions aimed at develop-
ing efficient policies for prevention, screening, and diagnosis [1]. 
Since cancer epidemiology always needs good quality information 
for establishing reliable health-care policies worldwide, in this 
brief report, we provide a concise overview on current cancer epi-
demiologic data garnered from the official databases of the World 
Health Organization (WHO) and American Cancer Society (ACS) 
in the attempt of providing updated information on frequency, 
mortality, and survival expectancy of the 15 leading types of cancers 
worldwide.
2. FREQUENCY OF MALIGNANT DISEASES
The last WHO update, corresponding to the year 2016, on the top 
20 causes of disease burden estimated as cause-specific Disability- 
Adjusted Life Years (DALYs) is shown in Table 1 [2]. According 
to the WHO, cancers impose the largest worldwide burden (244.6 
million DALYs), both in men (137.4 million DALYs) and in women 
(107.1 million DALYs), followed by ischemic heart disease (203.7 
million DALYs) and stroke (137.9 million DALYs). The cancer- 
related burden is slightly but nonsignificantly higher in men than 
in women (9.6% vs 8.6%; p = 0.219). The largest number of DALYs 
is obviously found after the age of 60 years (124.2 million DALYs; 
50.8%). Leukemias (37%), followed by brain and nervous system 
cancers (16%) and lymphomas (13%), are the most prevalent malig-
nant diseases in subjects aged 14 years or younger. In the age range 
15–49 years, breast cancer (13%) is the most common malignancy, 
followed by liver (12%) and lung (9%) cancers. In the age range 
50–59 years, lung cancer is the most frequent malignant disease 
(18%), followed by liver (11%) and breast (9%) cancers, while the 
most frequent malignancies in subjects aged 60 years or older are 
lung (21%), colorectal (9%), stomach (9%), and liver cancers (9%).
The list of the most frequent cancers from the WHO Global Cancer 
Observatory (GLOBOCAN) 2018 registry is shown in Table 2 [3]. 
Overall, 18.08 million new cases of cancer have been diagnosed in 
2018 in which lung (with trachea and bronchus, 2.09 million cases), 
breast (2.09 million cases), and prostate (1.28 million cases) being 
the three most frequent. In men, lung (1.37 million cases) and pros-
tate (1.28 million cases) cancers are still in the first and second posi-
tions, while stomach (0.68 million cases) is third, followed by liver 
(and intrahepatic bile ducts, 0.60 million cases) cancer. In women, 
breast cancer is by far the most frequent (2.09 million cases), fol-
lowed by lung (0.72 million cases), cervix uteri (0.57 million cases) 
and colon (0.58) cancers. Notably, colon and rectal cancers alto-
gether (i.e., colorectal cancer) would be the third overall most 
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A B S T R AC T
In this brief report, we offer a concise overview on current cancer epidemiology garnered from the official databases of World 
Health Organization and American Cancer Society and provide recent information on frequency, mortality, and survival 
expectancy of the 15 leading types of cancers worldwide. Overall, cancer poses the highest clinical, social, and economic burden 
in terms of cause-specific Disability-Adjusted Life Years (DALYs) among all human diseases. The overall 0–74 years risk of developing 
cancer is 20.2% (22.4% in men and 18.2% in women, respectively). A total number of 18 million new cases have been diagnosed in 
2018, the most frequent of which are lung (2.09 million cases), breast (2.09 million cases), and prostate (1.28 million cases) cancers. 
Beside sex-specific malignancies, the ratio of frequency between men and women is >1 for all cancers, except thyroid (i.e., 0.30). 
As concerns mortality, cancer is the second worldwide cause of death (8.97 million deaths) after ischemic heart disease, but will 
likely become the first in 2060 (~18.63 million deaths). Lung, liver, and stomach are the three most deadly cancers in the general 
population, while lung and breast cancers are the leading causes of cancer related-mortality in men and women, respectively. 
Prostate and thyroid cancers have the best prognosis, with 5-year survival ~100%, while esophagus, liver, and especially pancreas 
cancers have the worst prognosis, typically <20% at 5 years. We hope that this report will provide fertile ground for addressing 
health-care interventions aimed at preventing, diagnosing, and managing cancer around the world.
© 2019 Atlantis Press International B.V. 
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
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Table 2 | List of the most frequent cancers from the World Health Organization (WHO) Global Cancer Observatory (GLOBOCAN) 2018 
Cancer
Incidence (million) Risk 0–74 years (%)
Total Men Women Ratio Age-standardized Total Men Women
All cancers 18.079 9.456 8.623 1.10 197.9 20.2 22.41 18.25
Lung (and trachea and bronchus) 2.094 1.369 0.725 1.89 22.5 2.75 3.8 1.77
Breast 2.088 – 2.088 – 46.3 – – 5.03
Prostate 1.276 1.276 – – 29.3 – 3.73 –
Colon 1.097 0.576 0.521 1.11 11.5 1.31 1.51 1.12
Stomach 1.034 0.684 0.350 1.95 11.1 1.31 1.87 0.79
Liver (and intrahepatic bile ducts) 0.841 0.597 0.245 2.44 9.3 1.08 1.61 0.57
Rectum 0.704 0.430 0.274 1.57 7.7 0.91 1.2 0.65
Esophagus 0.572 0.400 0.172 2.32 6.3 0.78 1.15 0.43
Cervix uteri 0.570 – 0.570 – 13.1 – – 1.36
Thyroid 0.567 0.131 0.436 0.30 6.7 0.68 0.33 1.03
Bladder 0.549 0.424 0.125 3.38 5.7 0.65 1.08 0.27
Non-Hodgkin’s lymphoma 0.510 0.285 0.225 1.27 5.7 0.61 0.72 0.51
Pancreas 0.459 0.243 0.216 1.13 4.8 0.55 0.65 0.45
Leukemia 0.437 0.249 0.188 1.33 5.2 0.48 0.57 0.4
Kidney 0.403 0.255 0.149 1.71 4.5 0.52 0.69 0.35
frequent cancer (1.80 million cases) as well as the second most 
frequent malignancy in women (0.79 million cases) and the third 
most frequent in men (0.98 million cases), respectively. Regarding 
the prevalence, the Global Burden of Diseases, Injuries, and 
Risk Factors Study has recently reported a value of 100.48 million 
cases for the year 2017, displaying a 1.59-fold increase from the 
year 1990 [4].
Breast cancer reaches the highest age-standardized frequency 
(46.3 per 100,000), followed by prostate (29.3 per 100,000), lung 
(22.5 per 100,000), colorectal (19.2 per 100,000), cervix uteri (13.1 
per 100,000), and stomach (11.1 per 100,000). The overall risk of 
developing cancer between the age of 0–74 years is 20.2% (22.4% 
in men and 18.2% in women, respectively); the highest risk of 
malignancy is for lung (3.80%), prostate (3.73%), and colorectal 
(2.71%) cancers in men and for breast (5.03%), colorectal and lung 
(both 1.77%), and cervix uteri (1.36) in women. Beside sex- specific 
malignancies, the ratio of frequency in men and women is >1 for 
all cancers, except thyroid (i.e., 0.30). The highest men/women 
ratio is for bladder (3.38), liver and intrahepatic bile ducts (2.44), 
and esophagus (2.32) [3].
3. MORTALITY FOR MALIGNANT DISEASES
The last WHO update, corresponding to the year 2016, on 
the top 20 causes of disease mortality is shown in Table 3 [2]. 
Briefly, ischemic heart disease remains the leading cause of 
Table 1 | World Health Organization (WHO) Global Health Estimates 2016 on the 20 leading causes of disease burden, estimated as cause-specific DALYs 
Disease
Overall Men Women
DALYs† Percentage (%) Rank DALYs† Percentage (%) Rank DALYs† Percentage (%) Rank
Total 2668.475 100 – 1429.691 100 – 1238.785 100 –
Cancers 244.574 9.2 1 137.439 9.6 1 107.135 8.6 1
Ischemic heart disease 203.700 7.6 2 119.756 8.4 2 83.945 6.8 2
Stroke 137.941 5.2 3 72.910 5.1 3 65.031 5.2 3
Lower respiratory infections 129.690 4.9 4 67.542 4.7 4 62.148 5.0 4
Preterm birth complications 101.397 3.8 5 55.618 3.9 6 45.779 3.7 5
Road injury 82.538 3.1 6 60.616 4.2 5 21.922 1.8 13
Diarrheal diseases 81.743 3.1 7 41.412 2.9 7 40.331 3.3 6
COPD 72.512 2.7 8 41.411 2.9 8 31.101 2.5 7
Birth asphyxia and birth trauma 63.928 2.4 9 35.844 2.5 9 28.084 2.3 8
HIV/AIDS 59.951 2.2 10 33.995 2.4 10 25.956 2.1 11
Parasitic and vector diseases 51.838 1.9 11 26.244 1.8 13 25.594 2.1 12
Tuberculosis 51.643 1.9 12 33.020 2.3 11 18.622 1.5 15
Back and neck pain 47.515 1.8 13 21.089 1.5 18 26.427 2.1 10
Cirrhosis of the liver 45.287 1.7 14 31.107 2.2 12 14.179 1.1 18
Depressive disorders 44.175 1.7 15 17.453 1.2 20 26.722 2.2 9
Kidney diseases 39.079 1.5 16 21.353 1.5 17 17.726 1.4 16
Neonatal sepsis and infections 39.009 1.5 17 20.095 1.4 19 18.913 1.5 14
Falls 38.162 1.4 18 22.210 1.6 16 15.953 1.3 17
Self-harm 37.564 1.4 19 23.801 1.7 15 13.763 1.1 19
Interpersonal violence 31.237 1.2 20 24.322 1.7 14 6.914 0.9 20
†Million DALYs. COPD, chronic obstructive pulmonary disease; DALYs, disability-adjusted life years.
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Deaths† Rank Percentage (%) Deaths† Rank Percentage (%)
Total 56.874 100 52.307 100 9
Ischemic heart disease 9.433 1 16.6 7.029 1 13.4 34
Cancers 8.966 2 15.8 7.010 2 13.4 28
Stroke 5.781 3 10.2 5.170 3 9.9 12
COPD 3.041 4 5.3 2.972 5 5.7 2
Lower respiratory infections 2.957 5 5.2 3.325 4 6.4 −11
AD and other dementias 1.992 6 3.5 0.804 15 1.5 148
Road injury 1.402 7 2.5 1.136 10 2.2 23
Diarrheal diseases 1.383 8 2.4 2.246 6 4.3 −38
Tuberculosis 1.293 9 2.3 1.684 7 3.2 −23
Cirrhosis of the liver 1.254 10 2.2 0.988 13 1.9 27
Kidney diseases 1.180 11 2.1 0.727 17 1.4 62
Other circulatory diseases 1.081 12 1.9 0.840 14 1.6 29
Preterm birth complications 1.013 13 1.8 1.382 9 2.6 −27
HIV/AIDS 1.012 14 1.8 1.469 8 2.8 −31
Hypertensive heart disease 0.898 15 1.6 0.619 18 1.2 45
Self-harm 0.793 16 1.4 0.790 16 1.5 0
Birth asphyxia and trauma 0.679 17 1.2 1.125 11 2.2 −40
Falls 0.660 18 1.2 0.462 20 0.9 43
Parasitic and vector diseases 0.616 19 1.1 1.025 12 2.0 −40
Interpersonal violence 0.477 20 0.8 0.495 19 0.9 −4
†Million deaths. AD, Alzheimer’s disease; COPD, chronic obstructive pulmonary disease. 
death, accounting for 9.43 million deaths worldwide, followed 
by cancer (8.97 million deaths) and stroke (5.78 million deaths). 
An analysis of the trend in the past 15 years shows that isch-
emic heart disease and cancer have undergone a rather similar 
increase (i.e., +34% and +28%, respectively), which is however 
more than threefold higher than the trend of total mortality 
during the same period (i.e., from 52.31 to 56.87 million deaths; 
+9%). Regarding other causes of death, mortality for Alzheimer’s 
disease and other dementias has increased by 148%, while that 
for birth asphyxia and birth trauma, for parasitic and vector dis-
eases, for diarrheal diseases, or for HIV/AIDS has decreased by 
more than 30%. This is also mirrored by the different positions 
of these conditions in the list from 2000 to 2006. Notably, the 
rank of cancer among the leading causes of mortality varies in 
the different WHO Regions, being first in the Western Pacific 
and America Regions, second in the South-East Asia, European, 
and Eastern Mediterranean Regions, but only fourth in the 
African Region (Table 4) [2].
Table 4 | Leading causes of mortality in the different regions of the World Health Organization (2016) 
Disease Western Pacific† Africa† Americas† South-East Asia† Europe† Eastern Mediterranean†
Total 13.778 8.845 6.876 13.819 9.215 4.122
Ischemic heart disease 2.391 0.512 1.091 2.234 2.342 0.835
Cancers 3.141 0.524 1.348 1.361 2.121 0.410
Stroke 2.393 0.373 0.437 1.250 0.986 0.326
Lower respiratory infections 0.470 0.917 0.311 0.783 0.245 0.221
Preterm birth complications 0.055 0.344 0.045 0.364 0.024 0.181
Cirrhosis of the liver 0.215 0.174 0.149 0.402 0.177 0.130
Road injury 0.343 0.284 0.157 0.409 0.078 0.128
Birth asphyxia and birth trauma 0.040 0.323 0.018 0.170 0.010 0.117
Diarrheal diseases 0.032 0.653 0.035 0.526 0.021 0.116
COPD 1.040 0.118 0.368 1.044 0.349 0.114
Kidney diseases 0.289 0.081 0.181 0.376 0.140 0.105
AD disease and other dementias 0.671 0.091 0.352 0.279 0.481 0.103
Tuberculosis 0.109 0.405 0.019 0.651 0.027 0.082
Hypertensive heart disease 0.313 0.072 0.111 0.181 0.157 0.058
Other circulatory diseases 0.229 0.135 0.218 0.097 0.342 0.057
Interpersonal violence 0.037 0.106 0.178 0.080 0.030 0.045
Falls 0.149 0.071 0.073 0.250 0.083 0.032
Self-harm 0.192 0.075 0.097 0.257 0.141 0.026
Parasitic and vector diseases 0.028 0.473 0.015 0.078 0.002 0.020
HIV/AIDS 0.037 0.719 0.054 0.126 0.058 0.017
†Million deaths. AD, Alzheimer’s disease; COPD, chronic obstructive pulmonary disease.
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Figure 1 | Estimated epidemiologic trend of the fifth leading cause of death 
from years 2016 to 2060. COPD, chronic obstructive pulmonary disease.
Table 5 | List of cancers with the highest morality rate from the World Health Organization (WHO) Global Cancer Observatory (GLOBOCAN) 2018 
Cancer
Mortality (million) Risk 0–74 years (%) Death rate 
(%)Total Men Women Ratio Age-standardized Total Men Women
All cancers 9.555 5.386 4.169 1.29 101.1 10.63 12.71 8.7 53
Lung (and trachea and bronchus) 1.761 1.185 0.576 2.06 18.6 2.22 3.19 1.32 84
Liver (and intrahepatic bile ducts) 0.781 0.548 0.233 2.35 8.5 0.98 1.46 0.53 93
Stomach 0.783 0.513 0.269 1.91 8.2 0.95 1.36 0.57 76
Breast 0.627 – 0.627 – 13.0 – – 1.41 30
Colon 0.551 0.290 0.261 1.11 5.4 0.54 0.66 0.44 50
Esophagus 0.509 0.357 0.151 2.36 5.5 0.67 1.00 0.36 89
Pancreas 0.432 0.227 0.205 1.11 4.4 0.50 0.59 0.41 94
Thyroid 0.411 0.156 0.255 0.61 0.42 0.05 0.04 0.05 7
Prostate 0.359 0.359 – – 7.6 – 0.60 – 28
Cervix uteri 0.311 – 0.311 – 6.9 – – 0.77 55
Rectum 0.310 0.184 0.126 1.46 3.2 0.35 0.46 0.26 44
Leukemia 0.309 0.180 0.129 1.39 3.5 0.33 0.40 0.26 71
Non-Hodgkin’s lymphoma 0.249 0.146 0.103 1.42 2.6 0.27 0.35 0.21 49
Bladder 0.200 0.148 0.052 2.87 1.9 0.18 0.29 0.08 36
Kidney 0.175 0.114 0.061 1.86 1.8 0.20 0.28 0.12 43
The list of the leading causes of cancer deaths from the GLOBOCAN 
2018 registry is shown in Table 5 [3]. The position in the mortality 
rank does not completely overlap with that in the frequency rank, 
since the death rate (calculated as the ratio between frequency and 
mortality) is obviously higher for certain type of malignancies than 
for others. Overall, lung (with trachea and bronchus), liver (with 
intrahepatic bile ducts), and stomach are the three most deadly can-
cers. In men these three cancers are still in the first three positions, 
while prostate becomes fifth, just after esophagus cancer. Unlike 
in the male sex, breast cancer is the leading cause of mortality in 
women, followed by lung (with trachea and bronchus) and stomach 
cancers. Notably, colon and rectal cancers altogether (i.e., colorec-
tal cancer) are the second leading overall cause of cancer death as 
well as the fourth cause of cancer mortality in men and women.
The overall risk of dying for cancer between the age of 0–74 years is 
10.6% (12.7% in men and 8.7% in women, respectively); the highest 
risk of malignancy is for lung (3.19%), liver (1.46%), and stomach 
(1.36%) in men and for breast (1.41%), lung (1.32%), and cervix 
uteri (0.77%) in women. Beside sex-specific malignancies, the ratio 
of mortality between men and women is >1 for all cancers except 
thyroid (i.e., 0.61). The highest men/women ratio is for bladder 
(2.87), esophagus (2.36), and liver and intrahepatic bile ducts (2.35) 
cancers. The death rate is the highest for pancreatic cancer (94%), 
followed by liver and intrahepatic bile ducts (93%), esophagus 
(89%), and trachea, bronchus, and lung (84%) cancers, while is the 
lowest for thyroid malignancies (7%) and is also relatively low for 
prostate (28%) and bladder (36%) cancers.
The WHO estimated epidemiologic trend of the fifth leading cause 
of death, from years 2016 to 2060, is shown in Figure 1 [5]. In the 
next four decades, cancer deaths are expected to overcome those 
for ischemic heart disease, with a 2.08-fold increase (1.76-fold for 
increase in ischemic heart disease) by the year 2060. Therefore, 
malignancies will become the leading causes of mortality around 
the world immediately after the year 2030 (Figure 1). Only chronic 
obstructive pulmonary disease deaths will rise sharper than cancer 
(2.32-fold increase) according to the WHO estimates, while the 
increase of stroke (1.86-fold) and lower respiratory infections 
(1.56-fold) will be lower. Providing that these projections will be 
confirmed, the rate of the overall population dying because of 
cancer will increase from 0.12% to 0.18% in the next four decades, 
while those who will die for ischemic heart disease will increase 
from 0.13% to 0.16% during the same period.
The estimated epidemiologic trend of the five leading causes of 
cancer death from years 2016 to 2060 is shown in Figure 2 [5]. Four 
of these malignancies are already included among the list of 20 
leading causes of death worldwide (lung cancer is sixth, liver cancer 
is 16th, colorectal cancer is 17th, and stomach cancer is 19th). The 
mortality rate of all these five malignancies is predicted to increase 
sharply from 1.43-fold (lung cancers) up to 2.53-fold (breast 
cancer) in the next 40 years. Colon cancer (2.15-fold increase) will 
likely overcome liver cancer (2.00-fold increase), while stomach 
cancer will remain at the fourth place (2.07-fold increase). Notably, 
in 2016, prostate and esophagus cancers made their appearance in 
the list of the 20 leading causes of death around the world (lung 
cancer at 8th, colorectal cancer 12th, liver cancer 13th, stomach 
cancer 14th, breast cancer 17th, prostate cancer 18th, and esopha-
gus cancer 20th positions) [5].
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Figure 2 | Estimated epidemiologic trend of the five leading causes of 
cancer death from years 2016 to 2060.
4. PROGNOSIS OF MALIGNANT DISEASES
According to the ACS, the prognosis of the 15 most frequent types 
of cancer, inclusive of 5-year relative survival rate at different stages, 
is shown in Figure 3 [6]. Thyroid and prostate cancers have the 
best overall diagnosis, approximating 100% survival at 5 years, and 
78% and 30% survival at 5 years for cancers with distant metasta-
ses. Unlike these malignancies, the esophagus, liver, and especially 
pancreas cancers have the worst overall prognosis, typically <20%. 
Notably, advanced stomach, bladder, esophagus, liver, and pancreas 
cancers have a 5-year survival ≤5%.
Valuable information can also be garnered from the global surveil-
lance of trends in cancer survival 2000–14 (CONCORD-3) study, 
which is based on individual records of as over 37.5 million patients 
with one of 18 cancers in 71 different countries [7]. Overall, the 
Figure 3 | Prognosis of the 15 most frequent types of cancer, inclusive  
of 5-year relative survival rate at different stages, according to the 
American Cancer Society (ACS). †Trachea, bronchus, and lung, ‡Liver  
and intrahepatic bile ducts.
cumulative 5-year survival of the most frequent cancers was as 
follows (in decreasing order): prostate 70–100%, breast 80–85%, 
rectum 60–70%, colon and cervix 50–70%, ovary 30–50%, stomach 
and brain 20–40%, esophagus 10–30%, lung 10–20%, liver 5–30%, 
and pancreas 5–15%, respectively.
5. CONCLUSION
The current epidemiologic data and, even more troublingly, the 
incremental trend of cancer frequency, prevalence, and mortality 
expected in the next 40 years suggest that the burden of malig-
nant diseases is, and will remain for long, of epidemic proportion. 
Malignant diseases can be regarded as the first and foremost public 
health-care issue, which impose a dramatic clinical burden, disrupt 
social standards, and erode a huge amount of economic resources. 
Hence, it seems necessary that national governments and supra-
national organizations will embark in landmark efforts for estab-
lishing or reinforcing the current strategies for cancer prevention, 
screening, diagnosis, and management. A global strategy shall then 
be designed, based on major investments for screening and treat-
ing patients, better funding for promoting the scientific research 
against cancer, and collaborative efforts to make cancer care more 
efficient and sustainable. Notably, some disruptive technologies 
have also recently appeared, which hold great promise for revolu-
tionizing cancer care. These basically include (i) liquid biopsy [8], 
which will enable a more efficient screening, diagnosis, and thera-
peutic monitoring, (ii) personalized medicine [9], which will help 
dissecting the interindividual variability of cancers and defining 
personalized and more efficient treatments, (iii) immunotherapy, 
which is a highly effective means for restoring or improving 
immune system function against malignant cells [10], along with 
(iv) digital epidemiology [11], which will facilitate to secure disease 
information earlier than conventional health epidemiology.
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